In imatinib-resistant CML cells, the use of SIRT1-specific blockers EX527/amurensin6 and Sirtol/Tenovin9 is associated with blockade recurrence and relapse, potentiation of proliferation inhibition, and induction of apoptosis in the presence of imatinib and chemosensitization by blockade of SIRT1. This evidence concerns the gene SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive.